Regional differences in sorafenib-treated patients with hepatocellular carcinoma

GIDEON observational study

Masatoshi Kudo, Riccardo Lencioni, Jorge A. Marrero, Alan P. Venook, Jean Pierre Bronowicki, Xiao Ping Chen, Lucy Dagher, Junji Furuse, Jean Francois H Geschwind, Laura Ladrón de Guevara, Christos Papandreou, Arun J. Sanyal, Tadatoshi Takayama, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Sheng Long Ye

Research output: Contribution to journalArticle

Abstract

Background & Aims: Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. Methods: GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. Results: 3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1–24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8–25.0 months). Conclusions: Data from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.

Original languageEnglish (US)
Pages (from-to)1196-1205
Number of pages10
JournalLiver International
Volume36
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Observational Studies
Hepatocellular Carcinoma
Japan
Registries
Therapeutics
Latin America
sorafenib
Liver Neoplasms
Safety

Keywords

  • GIDEON
  • hepatocellular carcinoma
  • liver
  • Nexavar
  • sorafenib

ASJC Scopus subject areas

  • Hepatology

Cite this

Kudo, M., Lencioni, R., Marrero, J. A., Venook, A. P., Bronowicki, J. P., Chen, X. P., ... Ye, S. L. (2016). Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver International, 36(8), 1196-1205. https://doi.org/10.1111/liv.13096

Regional differences in sorafenib-treated patients with hepatocellular carcinoma : GIDEON observational study. / Kudo, Masatoshi; Lencioni, Riccardo; Marrero, Jorge A.; Venook, Alan P.; Bronowicki, Jean Pierre; Chen, Xiao Ping; Dagher, Lucy; Furuse, Junji; Geschwind, Jean Francois H; Ladrón de Guevara, Laura; Papandreou, Christos; Sanyal, Arun J.; Takayama, Tadatoshi; Yoon, Seung Kew; Nakajima, Keiko; Lehr, Robert; Heldner, Stephanie; Ye, Sheng Long.

In: Liver International, Vol. 36, No. 8, 01.08.2016, p. 1196-1205.

Research output: Contribution to journalArticle

Kudo, M, Lencioni, R, Marrero, JA, Venook, AP, Bronowicki, JP, Chen, XP, Dagher, L, Furuse, J, Geschwind, JFH, Ladrón de Guevara, L, Papandreou, C, Sanyal, AJ, Takayama, T, Yoon, SK, Nakajima, K, Lehr, R, Heldner, S & Ye, SL 2016, 'Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study', Liver International, vol. 36, no. 8, pp. 1196-1205. https://doi.org/10.1111/liv.13096
Kudo, Masatoshi ; Lencioni, Riccardo ; Marrero, Jorge A. ; Venook, Alan P. ; Bronowicki, Jean Pierre ; Chen, Xiao Ping ; Dagher, Lucy ; Furuse, Junji ; Geschwind, Jean Francois H ; Ladrón de Guevara, Laura ; Papandreou, Christos ; Sanyal, Arun J. ; Takayama, Tadatoshi ; Yoon, Seung Kew ; Nakajima, Keiko ; Lehr, Robert ; Heldner, Stephanie ; Ye, Sheng Long. / Regional differences in sorafenib-treated patients with hepatocellular carcinoma : GIDEON observational study. In: Liver International. 2016 ; Vol. 36, No. 8. pp. 1196-1205.
@article{52baac53f0094800b3e399adc1391001,
title = "Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study",
abstract = "Background & Aims: Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. Methods: GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. Results: 3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7{\%} vs 9.1–24.3{\%}). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4{\%}) and Asia-Pacific (67.2{\%}) compared with the USA (49.4{\%}) and Europe (43.5{\%}). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8–25.0 months). Conclusions: Data from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.",
keywords = "GIDEON, hepatocellular carcinoma, liver, Nexavar, sorafenib",
author = "Masatoshi Kudo and Riccardo Lencioni and Marrero, {Jorge A.} and Venook, {Alan P.} and Bronowicki, {Jean Pierre} and Chen, {Xiao Ping} and Lucy Dagher and Junji Furuse and Geschwind, {Jean Francois H} and {Ladr{\'o}n de Guevara}, Laura and Christos Papandreou and Sanyal, {Arun J.} and Tadatoshi Takayama and Yoon, {Seung Kew} and Keiko Nakajima and Robert Lehr and Stephanie Heldner and Ye, {Sheng Long}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/liv.13096",
language = "English (US)",
volume = "36",
pages = "1196--1205",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Regional differences in sorafenib-treated patients with hepatocellular carcinoma

T2 - GIDEON observational study

AU - Kudo, Masatoshi

AU - Lencioni, Riccardo

AU - Marrero, Jorge A.

AU - Venook, Alan P.

AU - Bronowicki, Jean Pierre

AU - Chen, Xiao Ping

AU - Dagher, Lucy

AU - Furuse, Junji

AU - Geschwind, Jean Francois H

AU - Ladrón de Guevara, Laura

AU - Papandreou, Christos

AU - Sanyal, Arun J.

AU - Takayama, Tadatoshi

AU - Yoon, Seung Kew

AU - Nakajima, Keiko

AU - Lehr, Robert

AU - Heldner, Stephanie

AU - Ye, Sheng Long

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background & Aims: Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. Methods: GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. Results: 3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1–24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8–25.0 months). Conclusions: Data from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.

AB - Background & Aims: Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. Methods: GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. Results: 3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1–24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8–25.0 months). Conclusions: Data from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.

KW - GIDEON

KW - hepatocellular carcinoma

KW - liver

KW - Nexavar

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84978818900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978818900&partnerID=8YFLogxK

U2 - 10.1111/liv.13096

DO - 10.1111/liv.13096

M3 - Article

VL - 36

SP - 1196

EP - 1205

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 8

ER -